Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, ANG Lifesciences India has submitted that the total revenue of the Company in first quarter of Financial Year 2021-22 is Rs 118 crore. The Company has been able to show handsome growth in topline backed by persistent and focused efforts by the management in its goal of maintaining the growth trend going forward. The Company has entered into agreement for the supply of medicine with various state government across India worth Rs 250 crore and more, apart from the P to P business and export business worth Rs 100 crore. Further the Company expects to achieve the total sales of Rs 350 crore approximately in the current Financial Year 2021-22 with a healthy bottom-line.
The above information is a part of company’s filings submitted to BSE.
